Case-Based Learning: Fever With Discordant Biomarker and Clinical Trajectories

Abstract

Fever with discordant biomarker and clinical trajectories presents a multifaceted diagnostic and therapeutic challenge for clinicians. While biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), and erythrocyte sedimentation rate (ESR) are widely integrated in clinical algorithms to aid in diagnosis, risk stratification, and management of febrile patients, emerging evidence highlights scenarios where these markers diverge from the patient's clinical evolution. This review synthesizes current knowledge regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic dilemmas, and management strategies in such cases. It underscores the limitations of over-reliance on biomarkers, emphasizes the necessity of integrating serial clinical assessments, and discusses evidence-based approaches to optimize patient outcomes. Practical insights, recent advances, and international guideline recommendations are examined to equip healthcare professionals with a nuanced, mechanism-based framework for managing fever with discordant biomarker and clinical patterns.

Introduction

Fever remains one of the most common presenting complaints in clinical practice, often prompting extensive laboratory evaluation and empirical therapy. The integration of biomarkers such as CRP, PCT, and others has revolutionized the assessment of febrile syndromes. However, the increasing availability and reliance on these biomarkers have given rise to complex clinical scenarios where laboratory trajectories fail to reflect the clinical course, posing diagnostic and therapeutic uncertainties. Discordant trajectories, where biomarkers improve or worsen incongruently with the patient’s clinical status, demand careful interpretation to avoid misdiagnosis, inappropriate escalation, or premature de-escalation of therapy. This article explores the clinical implications, underlying mechanisms, and evidence-based strategies for case-based learning in the context of fever with discordant biomarker and clinical trajectories, aiming to enhance the diagnostic acumen and decision-making of healthcare professionals.

Epidemiology / Disease Burden

Fever is a universally encountered symptom across healthcare settings, accounting for a significant proportion of consultations in emergency departments, inpatient wards, and outpatient clinics. Studies estimate that up to 40% of hospital inpatients develop fever during their stay, with infection, inflammatory, and malignant etiologies being predominant. The use of biomarkers to differentiate between bacterial and non-infectious causes has become standard practice; yet, discordance between biomarker trends and patient improvement or deterioration is increasingly reported, especially in sepsis, autoimmune conditions, and post-operative states. This discordance is associated with prolonged hospitalization, increased healthcare costs, and a higher risk of diagnostic error, underscoring its clinical relevance and the need for robust, evidence-guided approaches.

Pathophysiology

The pathophysiological basis for discordant biomarker and clinical trajectories in fever is multifactorial. Biomarkers such as CRP and PCT are surrogate markers of systemic inflammation, produced in response to cytokine activation and microbial products. However, their levels are influenced by numerous non-infectious factors including tissue injury, trauma, autoimmune activity, renal or hepatic dysfunction, and pharmacologic modulation (e.g., corticosteroids, immunosuppressants). Additionally, the temporal kinetics of biomarker rise and fall may lag behind clinical improvement or deterioration, with CRP peaking at 24–48 hours and normalizing over days, while PCT responds more rapidly to bacterial insult but may remain elevated in systemic inflammatory response syndrome (SIRS) or after major surgery. Genetic polymorphisms, immune dysregulation, and underlying comorbidities further contribute to the complexity, challenging the interpretation of isolated biomarker values.

Risk Factors

Several risk factors predispose patients to discordant biomarker and clinical trajectories, including advanced age, immunosuppression (such as in transplant recipients or those on chronic corticosteroids), chronic kidney or liver disease, malignancy, and recent surgical interventions. Patients with autoimmune or autoinflammatory diseases, as well as those with atypical infections (e.g., viral, fungal, or mycobacterial), are particularly susceptible. Polypharmacy, especially with agents affecting immune response or inflammation, also modulates biomarker expression, underscoring the importance of comprehensive clinical assessment in these populations.

Clinical Features

Clinically, patients may present with persistent or recurrent fever despite normalization of biomarkers, or conversely, with ongoing biomarker elevation despite clear clinical improvement. For example, a patient recovering from pneumonia may exhibit declining CRP and PCT despite persistent fever due to drug fever or superimposed nosocomial infection. Alternatively, post-surgical patients may experience prolonged CRP elevation in the absence of infectious complications. Such discordance necessitates a holistic appraisal of the clinical context, careful review of temporal trends, and consideration of alternative diagnoses, including non-infectious inflammatory processes, drug reactions, thromboembolic events, or occult malignancy.

Diagnosis

Diagnostic evaluation in the setting of discordant biomarker and clinical trajectories should be systematic and iterative. Serial assessment of vital signs, physical examination findings, and organ function is paramount. Laboratory investigations should include repeat biomarker measurements, complete blood count with differential, renal and hepatic panels, and targeted microbiological or serological testing as indicated. Imaging modalities such as chest radiography, abdominal ultrasound, or CT scan should be employed judiciously to identify occult sources of infection or inflammation. Multidisciplinary input, including infectious disease, rheumatology, or hematology consultation, may be warranted in complex or refractory cases. Ultimately, diagnosis relies on the integration of dynamic clinical and laboratory data, rather than on static biomarker thresholds.

Treatment & Management

Management strategies should center on treating the underlying etiology while minimizing unnecessary interventions. Empirical antimicrobial therapy should be re-evaluated regularly in light of evolving clinical and laboratory data, with de-escalation considered when infection is unsubstantiated. Non-infectious causes including drug fever, autoimmune flare, or thromboembolic disease should be investigated and managed appropriately. Supportive care, vigilant monitoring, and interdisciplinary collaboration are essential. Importantly, clinicians should avoid knee-jerk escalation or premature discontinuation of therapy based solely on discordant biomarker trends, instead prioritizing patient-centered, evidence-based decision-making.

Recent Advances / Emerging Therapies

Recent advances in the interpretation of biomarkers have focused on integrating serial measurements, biomarker ratios (e.g., PCT/CRP), and multiplex panels to enhance diagnostic accuracy. Machine learning algorithms and clinical decision support tools are being developed to synthesize complex datasets and predict outcomes in febrile patients with discordant trajectories. Emerging research also explores the role of novel biomarkers including interleukin-6, presepsin, and cell-free DNA in differentiating infectious from non-infectious etiologies and guiding therapy. However, the clinical utility of these approaches remains under investigation, and their widespread adoption awaits further validation in prospective studies.

Guideline Recommendations

International guidelines from organizations such as the Infectious Diseases Society of America (IDSA) and Surviving Sepsis Campaign emphasize the importance of integrating clinical judgment with biomarker data in the management of febrile patients. They recommend against the use of biomarkers as sole determinants for initiating, escalating, or discontinuing antimicrobial therapy. Instead, guidelines advocate for serial clinical evaluations and multidisciplinary input, particularly in cases with discordant trajectories. Education on the limitations of biomarkers and the potential for misleading results is highlighted as a key component of quality patient care and antimicrobial stewardship programs.

Conclusion

Fever with discordant biomarker and clinical trajectories represents a growing diagnostic and management challenge in modern medicine. While biomarkers offer valuable adjunctive information, their limitations necessitate a comprehensive, patient-centered approach that integrates serial clinical assessments, targeted investigations, and multidisciplinary expertise. Awareness of risk factors, pathophysiological mechanisms, and guideline-based recommendations is essential to optimize outcomes, reduce unnecessary interventions, and foster prudent use of healthcare resources. Ongoing research and technological innovation hold promise for refining the role of biomarkers in complex febrile syndromes, but clinical acumen remains paramount.